Endocannabinoid system, a target to improve cognitive disorders in models of Down syndrome

(Universitat Pompeu Fabra - Barcelona) A study by the Neuropharmacology Laboratory-NeuroPhar of the Department of Experimental and Health Sciences (DCEXS) at UPF reveals the involvement of the endocannabinoid system in cognitive disorders in mouse models of Down syndrome. The work, led by Andr é s Ozaita and Rafael Maldonado, which has been published in the journal Neurobiology of Disease, also identifies cannabinoid receptor type-1 (CB1) as a potential treatment target.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news